Back to top
more

Bionano Genomics (BNGO)

(Delayed Data from NSDQ)

$0.78 USD

0.78
2,361,429

-0.03 (-4.19%)

Updated Apr 18, 2024 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy18.00%
3Hold9.44%
4Sell5.10%
5Strong Sell2.53%
S&P50011.08%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Bionano (BNGO) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Bionano Genomics (BNGO) is likely to provide updates on earnings and revenues when it reports second-quarter 2021 results.

Bionano Genomics, Inc. (BNGO) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Bionano Genomics, Inc. (BNGO) closed at $5.87, marking a -1.68% move from the previous day.

Bionano Genomics, Inc. (BNGO) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) closed the most recent trading day at $6.72, moving -1.47% from the previous trading session.

Bionano Genomics, Inc. (BNGO) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Bionano Genomics, Inc. (BNGO) closed at $7.15, marking a -1.38% move from the previous day.

Cummins, Century Aluminum, AMC Entertainment, Ashford Hospitality Trust and Bionano Genomics highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Cummins, Century Aluminum, AMC Entertainment, Ashford Hospitality Trust and Bionano Genomics highlighted as Zacks Bull and Bear of the Day

Shuvra Shankar Dey headshot

These 3 Meme Stocks Aren't as Risky as You May Think

by Shuvra Shankar Dey

Solid revenue and earnings growth prospects of AMC, AHT and BNGO make them relatively safer bets despite being favorites of retail trades on the meme frenzy.

Bionano Genomics, Inc. (BNGO) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) delivered earnings and revenue surprises of 0.00% and 13.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Bionano Genomics (BNGO) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Bionano Genomics (BNGO) stock based on the movements in the options market lately.

Bionano (BNGO) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Bionano Genomics (BNGO) is expected to provide updates on its earnings and revenues when it reports first-quarter 2021 result.

Bionano Genomics, Inc. (BNGO) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) closed the most recent trading day at $6.97, moving -1.13% from the previous trading session.

Has Bionano Genomics (BNGO) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Is (BNGO) Outperforming Other Medical Stocks This Year?

Bionano Genomics, Inc. (BNGO) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, Bionano Genomics, Inc. (BNGO) closed at $9.38, marking a -1.57% move from the previous day.

Implied Volatility Surging for Bionano Genomics (BNGO) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Bionano Genomics (BNGO) stock based on the movements in the options market lately.

Why Bionano Genomics (BNGO) Might Surprise This Earnings Season

by Zacks Equity Research

Bionano Genomics (BNGO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Bionano Genomics, Inc. (BNGO) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Bionano Genomics, Inc. (BNGO) closed at $9.84 in the latest trading session, marking a +1.13% move from the prior day.

Bionano (BNGO) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Bionano (BNGO) will provide updates on its revenues and earnings when it reports fourth-quarter and full-year 2020 results.

    Bionano Genomics, Inc. (BNGO) Gains As Market Dips: What You Should Know

    by Zacks Equity Research

    Bionano Genomics, Inc. (BNGO) closed at $11.80 in the latest trading session, marking a +1.29% move from the prior day.

    Bionano Genomics, Inc. (BNGO) Stock Sinks As Market Gains: What You Should Know

    by Zacks Equity Research

    Bionano Genomics, Inc. (BNGO) closed at $11.85 in the latest trading session, marking a -1.41% move from the prior day.

    New Strong Sell Stocks for October 22nd

    by Zacks Equity Research

    Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

    Bionano Genomics, Inc. (BNGO) Upgraded to Buy: What Does It Mean for the Stock?

    by Zacks Equity Research

    Bionano Genomics, Inc. (BNGO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

    Bionano Genomics, Inc. (BNGO) Upgraded to Buy: Here's Why

    by Zacks Equity Research

    Bionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

    Bionano (BNGO) to Report Q2 Earnings: What's in the Offing?

    by Zacks Equity Research

    Bionano's (BNGO) sales numbers will be in focus when it reports Q2 results later in the week.

    Bionano Genomics, Inc. (BNGO) Gains But Lags Market: What You Should Know

    by Zacks Equity Research

    Bionano Genomics, Inc. (BNGO) closed the most recent trading day at $0.79, moving +0.25% from the previous trading session.

    Company News for Jul 13, 2020

    by Zacks Equity Research

    Companies in the news are: BNGO, AMRX, ALT, EXPR

    What Makes Bionano Genomics, Inc. (BNGO) a New Strong Buy Stock

    by Zacks Equity Research

    Bionano Genomics, Inc. (BNGO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).